carbidopa monohydrate + levodopa: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
carbidopa monohydrate + levodopa: clinical details
Prescribing considerations
- Confirm the exact formulation because immediate-release tablets, modified-release tablets and intestinal gel are not directly interchangeable.
- Avoid abrupt reduction or withdrawal.
- Assess somnolence, orthostatic symptoms, mental state, impulse-control behaviours and dopamine dysregulation syndrome.
- Duodopa is for advanced levodopa-responsive disease after inadequate control with available medicine combinations; assess pump, PEG-J and caregiver suitability.
Contraindications and cautions
- Hypersensitivity to the active substances or excipients.
- Narrow-angle glaucoma.
- Concomitant non-selective MAO inhibition or selective MAO-A inhibition.
- Suspicious undiagnosed skin lesions or a history of melanoma.
- Product-specific contraindications differ: selected product information includes severe psychosis; Lecado and Duodopa also list severe heart failure, severe arrhythmia and acute stroke. Duodopa additionally lists conditions in which adrenergic agents are contraindicated.
Monitoring
- Motor response, dyskinesia, wearing-off and adherence.
- Lying and standing blood pressure, somnolence and sudden sleep onset.
- Hallucinations, depression, suicidality, impulse-control disorders and compulsive medicine use.
- Periodic skin assessment and, during extended therapy, hepatic, haematological, cardiovascular and renal function.
- For Duodopa: stoma and tube function, abdominal complications, recurrent motor fluctuations and signs or risk factors for polyneuropathy.
Clinical pharmacology
Levodopa is transported into the brain and converted to dopamine. Carbidopa inhibits peripheral aromatic L-amino-acid decarboxylase without materially crossing the blood–brain barrier, increasing cerebral levodopa availability and reducing peripheral dopamine formation. Modified-release tablets prolong absorption; intestinal infusion reduces within-person plasma fluctuation.
Formulation and product differences
- Immediate-release Orion tablets are oral; their score facilitates swallowing but does not provide equal portions.
- Lecado is a polymer-based modified-release tablet that must be swallowed whole and may have a slower onset than immediate-release co-careldopa.
- Duodopa is an intestinal gel delivered by a portable pump through a duodenal or jejunal tube and has additional procedure-, device- and gastrointestinal risks.
carbidopa monohydrate + levodopa preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 100 mg + 25 mg, 200 mg + 50 mg
Tablet
Route: Oral
Strengths: 12.5 mg + 50 mg, 25 mg + 100 mg
carbidopa monohydrate + levodopa interactions
Check prescribed, over-the-counter and complementary products with a pharmacist or prescriber. Important examples include:
Non-selective monoamine oxidase inhibitors and selective MAO-A inhibitors
These combinations are contraindicated.
Iron salts
Ferrous sulfate and ferrous gluconate can reduce absorption and clinical response.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.